Related Experiment Videos

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors

John Araujo1, Christopher Logothetis

  • 1Genitourinary Center, M.D. Anderson Cancer Centre, Houston, TX 77030, USA. johna@mdanderson.org

Cancer Treatment Reviews
|March 16, 2010
PubMed

Insights

SRC (a tyrosine kinase) inhibitors like dasatinib show promise in treating solid tumors by inhibiting cancer growth and spread. Clinical trials are ongoing to confirm dasatinib

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • SRC tyrosine kinase is implicated in cancer development, invasion, and bone metastasis.
  • SRC inhibitors are a focus for solid tumor therapeutics.
  • Dasatinib is a leading SRC inhibitor under investigation.

Purpose of the Study:

  • To evaluate dasatinib's efficacy as a therapeutic agent in solid tumors.
  • To explore dasatinib's mechanism of action, including its effects on proliferation, invasion, and osteoclast activity.
  • To assess the potential of dasatinib in combination therapies.

Main Methods:

  • Preclinical studies using various solid tumor cell lines (prostate, breast, glioma).
  • In vitro assays assessing cell proliferation, invasion, and metastasis.
  • Evaluation of osteoclast activity inhibition.
  • Analysis of combination effects with cytotoxic agents and targeted therapies.
  • Review of emerging clinical data from Phase 1 and 2 trials.

Main Results:

  • Dasatinib demonstrated cytostatic effects, inhibiting cell proliferation, invasion, and metastasis in preclinical models.
  • Dasatinib effectively inhibited osteoclast activity, crucial for bone metastasis.
  • Preclinical studies indicated additive or synergistic effects when dasatinib was combined with other agents.
  • Early clinical data suggest dasatinib exhibits activity as a single agent and in combination therapies across various solid tumors.

Conclusions:

  • Dasatinib is a promising SRC inhibitor with demonstrated preclinical and early clinical activity against solid tumors.
  • Its ability to inhibit cancer cell proliferation, invasion, metastasis, and osteoclast activity supports its therapeutic potential.
  • Combination strategies involving dasatinib warrant further investigation in clinical trials.
  • Future research will further elucidate the clinical utility of SRC inhibition with dasatinib in cancer treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...